Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects 

Stock Information for Moleculin Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Moleculin Biotech Inc.

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal "MIRACLE" Phase 3 AML Trial on Pace for Q1 2026
Moleculin Announces New Annamycin Collaboration in Brain Tumors
Moleculin to Participate in the Virtual Investor Closing Bell Series
Moleculin Announces Reverse Stock Split
Moleculin Reports 60% of First 45 Subjects in Pivotal "MIRACLE" Phase 3 AML Trial Consented

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.